Allergan's Fishing For Deals, But Don't Expect A Big Catch
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its deal-making net.